Has Paul Casey, MD received payments from drug or device companies?

Yes. Drug and device makers reported $920 in general payments to Paul Casey, MD across 26 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Paul Casey, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Paul Casey, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Paul Casey, MD

Ophthalmology · Las Vegas, NVNPI 1538180302

Payments from drug & device makers

$920in general payments, 2019–2025

Across 26 payments — averaging $35.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alcon$342
Biotissue Holdings Inc.$163
Glaukos Corporation$145
AbbVie$52
NEW World Medical,inc.$40
Carl Zeiss Meditec AG$39
plus $140 from 6 others

What the payments were for

Food & beverage$88196%
Gifts$394%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alcon	8	$342
Biotissue Holdings Inc.	2	$163
Glaukos Corporation	3	$145
AbbVie	2	$52
NEW World Medical,inc.	1	$40
Carl Zeiss Meditec AG	2	$39
Novartis	2	$35
Sight Sciences, Inc.	2	$29
Sun Pharmaceutical Industries Inc.	1	$24
Kala Pharmaceuticals, Inc.	1	$19
Johnson & Johnson Surgical Vision, Inc.	1	$17
Bausch & Lomb, A Division Of Bausch Health US, LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$920 in reported general payments places this provider in the 35th percentile of 121 ophthalmology providers in Nevada.

See all ophthalmology providers in Nevada →

Medicare billing

Part B allowed, 2024

$1,649

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Las Vegas

Eva LiangLas Vegas$2.2M
Matthew SwanicLas Vegas$433K
Nelson LopezLas Vegas$193K
Kent WellishLas Vegas$185K
Allen ThachLas Vegas$173K
Steven LeibowitzLas Vegas$157K
Michael PernulaLas Vegas$149K
Matthew PezdaLas Vegas$136K
Mark DoubravaLas Vegas$66K
Emil SteinLas Vegas$57K

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →